Our extensive global network of manufacturing facilities in geographically diverse locations support our efforts to ensure reliable supply, and our facilities are routinely inspected by a number of health authorities globally.
Our pipeline fuels the future
Our pipeline of medicines is deep and diverse. We are a development house, focused on pipeline investments to continue moving up the value chain. We aim to develop more complex and novel products, providing greater opportunities to target gaps in patient care where others may not focus. We do this through a first-to-market emphasis and serving a key-pillar in our mission of expanding patient access. This means actively looking into opportunities to build a critical mass of new drugs submitted through the 505(b)(2) regulatory pathway and New Chemical Entities (NCEs). We also invest in life-cycle management of certain key products in our current portfolio, with a focus on making improvements to existing products and expanding formulations to make them more widely available to those who may not have previously had access.
Our pipeline and research and development capabilities, include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a wide range of therapeutic areas and product types. Some examples of our capabilities include:
- Biosimilars and insulin analogs
- Respiratory products
- Complex sterile products
- Topicals and transdermals
- Complex oral solid dosage forms
- High potency products
- Traditional generics
- Drug/device combinations
The information contained on this page is not for use in product detailing or promotion.
*Not all of the products listed have been approved for use in all countries. To learn which products have been approved for use in a particular country, please visit that country’s page for a full listing of available drug products.